SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Quest Diagnostics Incorporated (DGX) trades at a trailing P/E of 22.1, forward P/E of 18.3. Trailing earnings yield is 4.52%, forward earnings yield 5.48%. PEG 1.60. Graham Number is $114.89.
Criteria proven by this page:
- VALUE (44/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 18.3 (down from trailing 22.1) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 1.60 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield 4.52% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 5.48% as earnings recover.
- Analyst consensus target $215.10 (+10.8% upside) — modest upside expected.
Overall SharesGrow Score: 55/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
44/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — DGX
Valuation Multiples
P/E (TTM)22.1
Forward P/E18.3
PEG Ratio1.60
Forward PEG0.85
P/B Ratio3.06
P/S Ratio1.98
EV/EBITDA14.0
Per Share Data
EPS (TTM)$8.94
Forward EPS (Est.)$10.63
Book Value / Share$65.64
Revenue / Share$99.41
FCF / Share$12.24
Yields & Fair Value
Earnings Yield4.52%
Forward Earnings Yield5.48%
Dividend Yield1.65%
Graham Number$114.89
SharesGrow IV$305.38 (+57.3%)
Analyst Target$215.10 (+10.8%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
19.9 |
-2.89 |
2.78 |
1.71 |
1.73% |
| 2017 |
17.5 |
0.76 |
2.74 |
1.75 |
1.83% |
| 2018 |
15.4 |
-3.94 |
2.17 |
1.50 |
2.35% |
| 2019 |
16.7 |
0.93 |
2.54 |
1.85 |
2.00% |
| 2020 |
11.2 |
0.17 |
2.36 |
1.69 |
1.86% |
| 2021 |
10.8 |
0.22 |
3.36 |
2.00 |
1.43% |
| 2022 |
19.2 |
-0.39 |
3.08 |
1.84 |
1.68% |
| 2023 |
18.1 |
-2.77 |
2.45 |
1.67 |
2.03% |
| 2024 |
19.2 |
6.95 |
2.47 |
1.70 |
1.98% |
| 2025 |
19.4 |
1.42 |
2.69 |
1.75 |
1.83% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$4.51 |
$7.52B |
$645M |
8.6% |
| 2017 |
$5.50 |
$7.71B |
$772M |
10% |
| 2018 |
$5.29 |
$7.53B |
$736M |
9.8% |
| 2019 |
$6.29 |
$7.73B |
$858M |
11.1% |
| 2020 |
$10.52 |
$9.44B |
$1.43B |
15.2% |
| 2021 |
$15.53 |
$10.79B |
$2B |
18.5% |
| 2022 |
$7.98 |
$9.88B |
$946M |
9.6% |
| 2023 |
$7.52 |
$9.25B |
$854M |
9.2% |
| 2024 |
$7.69 |
$9.87B |
$871M |
8.8% |
| 2025 |
$8.75 |
$11.04B |
$992M |
9% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$10.64 |
$10.54 – $10.75 |
$11.76B |
$11.71B – $11.9B |
12 |
| 2027 |
$11.47 |
$11.22 – $11.85 |
$12.2B |
$11.87B – $12.56B |
12 |
| 2028 |
$12.49 |
$11.82 – $13.50 |
$12.76B |
$12.75B – $12.76B |
7 |
| 2029 |
$13.89 |
$13.50 – $14.19 |
$13.42B |
$13.13B – $13.65B |
2 |
